We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pharma major Lupin announced the receipt of the Establishment Inspection Report (EIR) after closure of the US FDA inspection of its Mandideep Unit II facility.